CONTROL OF ALPHAVIRUS REPLICATION IN THE NERVOUS SYSTEM
Project Number5R01NS038932-02
Contact PI/Project LeaderGRIFFIN, DIANE E
Awardee OrganizationJOHNS HOPKINS UNIVERSITY
Description
Abstract Text
DESCRIPTION: Sindbis virus (SV) is an alphavirus that infects neurons and
causes acute encephalomyelitis in mice. Non-fatal SV infection of the central
nervous system (CNS) of weanling mice elicits a well-characterized immune
response and provides a model system for studying mechanisms by which virus is
cleared from neural cells. Mice with severe combined immunodeficiency (SCID)
cannot clear virus and these mice develop persistent infection. The applicant
has shown by passive transfer experiments that antibody (Ab) is the primary
mechanism by which infectious virus is cleared from the CNS. Ab-mediated
control of intracellular virus replication is independent of complement and
leukocytes, is noncytolytic and requires cross-linking of the E2 glycoprotein
on the surface of the infected cell. Downregulation of SV replication is
associated with improved Na+K+ATPase-dependent control of cation flux and
results in restoration of host protein synthesis and response to type 1
interferons (IFNs). In mice this noncytotoxic mechanism for control of virus
replication results in persistence of viral RNA in the CNS and long-term local
production of antiviral Ab by B cells in the CNS. In the current application,
the applicant proposes to determine the mechanism by which Ab controls
intracellular virus replication in vivo and in vitro and the role of IFN in
this process through the following specific aims: (1) To define the required
specificity and cellular localization of antibody for effective control of
intracellular SV replication; (2) To determine the mechanism by which antibody
to the E2 glycoprotein of SV restores Na+K+ATPase function and controls
intracellular virus replication; (3) To determine the relative roles of
antibody, interferon and T cell cytokines for in vivo control of SV
replication.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
001910777
UEI
FTMTDMBR29C7
Project Start Date
01-July-2001
Project End Date
30-June-2005
Budget Start Date
01-July-2002
Budget End Date
30-June-2003
Project Funding Information for 2002
Total Funding
$286,125
Direct Costs
$175,000
Indirect Costs
$111,125
Year
Funding IC
FY Total Cost by IC
2002
National Institute of Neurological Disorders and Stroke
$286,125
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS038932-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS038932-02
Patents
No Patents information available for 5R01NS038932-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS038932-02
Clinical Studies
No Clinical Studies information available for 5R01NS038932-02
News and More
Related News Releases
No news release information available for 5R01NS038932-02
History
No Historical information available for 5R01NS038932-02
Similar Projects
No Similar Projects information available for 5R01NS038932-02